Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre study to characterize the safety and preliminary efficacy
of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory
non-Hodgkin´s lymphoma (NHL) who have received at least 1 prior therapy containing rituximab
(at least once).